Invus L.P. Amends Lexicon Pharmaceuticals Stake Filing

TL;DR

Invus L.P. updated its 13D filing for Lexicon Pharma on 7/29. Watch for changes.

AI Summary

Invus, L.P. filed an amendment to its Schedule 13D on July 29, 2024, regarding its beneficial ownership of Lexicon Pharmaceuticals, Inc. The filing indicates a change in the reporting person's holdings, though specific new percentages or dollar amounts are not detailed in this excerpt. The filing is an amendment to a previous filing, suggesting ongoing activity or adjustments in Invus's investment strategy concerning Lexicon Pharmaceuticals.

Why It Matters

This amendment signals potential shifts in a significant investor's position in Lexicon Pharmaceuticals, which could influence market perception and stock movement.

Risk Assessment

Risk Level: medium — Amendments to 13D filings often indicate changes in an investor's strategy or holdings, which can impact stock price and require close monitoring.

Key Players & Entities

• Invus, L.P. (company) — Filing entity
• Lexicon Pharmaceuticals, Inc. (company) — Subject company
• ARTAL GROUP S.A. (company) — Group member
• MR. AMAURY WITTOUCK (person) — Group member
• MR. RAYMOND DEBBANE (person) — Group member

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti

Filing Documents

• d777515dsc13da.htm (SC 13D/A) — 253KB
• d777515dex9928.htm (EX-99.28) — 36KB
• 0001193125-24-187770.txt ( ) — 291KB

of the Statement is hereby amended and restated in its entirety as follows

Item 2 of the Statement is hereby amended and restated in its entirety as follows: This statement is being filed jointly by Invus, L.P., a Bermuda limited partnership, Invus Advisors, L.L.C., a Delaware limited liability company, Invus Public Equities, L.P., a Bermuda limited partnership, Invus Public Equities Advisors, LLC, a Delaware limited liability company, Invus US Partners LLC, a Delaware limited liability company, Invus Global Management, LLC, a Delaware limited liability company, Siren, L.L.C., a Delaware limited liability company, Ulys, L.L.C., a Delaware limited liability company, Mr. Raymond Debbane, a citizen of Panama, Artal International S.C.A., a Luxembourg limited partnership, Artal International Management S.A., a Luxembourg société anonyme, Artal Group S.A., a Luxembourg société anonyme, Westend S.A., a Luxembourg société anonyme ( Westend ), Stichting Administratiekantoor Westend, a Netherlands foundation (the Stichting ), and Mr. Amaury Wittouck, a citizen of Belgium (collectively, the Reporting Persons ). The address of the principal place of business and principal office of Invus, L.P., Invus Public Equities, L.P., Invus US Partners LLC, Invus Global Management, LLC, Siren, L.L.C., Invus Advisors, L.L.C., Invus Public Equities Advisors, LLC and Ulys, L.L.C. is c/o The Invus Group, LLC, 750 Lexington Avenue, 30th Floor, New York, NY 10022. The business address for Mr. Debbane is c/o The Invus Group, LLC, 750 Lexington Avenue, 30th Floor, New York, NY 10022. The address of the principal place of business and principal office of Artal International S.C.A., Artal International Management S.A., Artal Group S.A., Westend and Mr. Amaury Wittouck is 44, Rue de la Vallée, L-2661, Luxembourg, Luxembourg. The address of the principal place of business and principal office of the Stichting is Claude Debussylaan, 46, 1082 MD Amsterdam, The Netherlands. In connection with the Reorganization, Invus Globa

(a), Item 5(b) and Item 5(c) of the Statement is each hereby amended and restated in its entirety as follows

Item 5(a), Item 5(b) and Item 5(c) of the Statement is each hereby amended and restated in its entirety as follows: The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items 2, 3 and 6 is incorporated by reference in its entirety into this Item 5. (a)-(b) Invus Public Equities, L.P. is the record and beneficial owner of 3,516,214 shares of Issuer Common Stock, representing approximately 1.4% of the outstanding shares of Issuer Common Stock. Invus Public Equities Advisors, LLC, as the general partner of Invus Public Equities, L.P., controls Invus Public Equities, L.P. and, accordingly, may be deemed to beneficially own the shares of Issuer Common Stock held by Invus Public Equities, L.P. Invus Global Management, LLC, as the managing member of Invus Public Equities Advisors, LLC, controls Invus Public Equities Advisors, LLC and, accordingly, may be deemed to beneficially own the shares of Issuer Common Stock that Invus Public Equities Advisors, LLC may be deemed to beneficially own. Siren, L.L.C., as the managing member of Invus Global Management, LLC, controls Invus Global Management, LLC and, accordingly, may be deemed to beneficially own the shares of Issuer Common Stock that Invus Global Management, LLC may be deemed to beneficially own. Mr. Raymond Debbane, as the managing member of Siren, L.L.C., controls Siren, L.L.C. and, accordingly, may be deemed to beneficially own the shares of Issuer Common Stock that Siren, L.L.C. may be deemed to beneficially own. Each of Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C. and Mr. Debbane disclaims such beneficial ownership. Invus, L.P. is the record owner of 35,402,689 shares of Issuer Common Stock and the beneficial owner of 38,918,903 shares of Issuer Common Stock, representing approximately 9.8% and approximately 10.8% of the outstanding shares of Issuer Common Stock, respectively.